Can Keytruda Sustain Merck's Growth Through the Rest of 2025?
MRK banks on Keytruda's soaring sales and new oncology strategies to fuel 2025 growth, even as competition and patent loss loom.
3 Fantastic Growth Stocks to Buy in August
Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.
SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus
Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.
Merck Stock Down 4% Since Q2 Results: How to Play the Stock
Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.
2 Beaten-Down Stocks With Incredible Upside Potential
Getting in on the ground floor with these companies might lead to superior returns.
Pandemic darlings Moderna, BioNTech are now on two different paths
The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find themselves on different paths.
Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?
MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth.
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results
Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, long-term investors should have a balanced approach to potentially positive data readouts.
This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich
Three years ago, Summit Therapeutics ( NASDAQ: SMMT ) was a little-known small-cap biotech that few investors with an average tolerance for risk would have bothered to pay attention to at the time. However, the company's shares have skyrocketed by more than 2,000% since then.As is often the case ...
3 Monster Stocks in the Making to Buy Right Now
Where can you find the next monster stocks? Check out the biotech space. It's not easy, but investors can sometimes find highly promising biotech stocks that are only in their early innings.Three Motley Fool contributors think they've identified monster stocks in the making.
Johnson & Johnson Raises FY25 Forecast, Joins Rigetti Computing, Unity Software, Brighthouse Financial And Other Big Stocks Moving Higher On Wednesday - BitMine Immersion Techs ( AMEX:BMNR ) , Brighthouse Finl ( NASDAQ:BHF )
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Wednesday. Shares of Johnson & Johnson JNJ rose sharply during Wednesday's session after the company raised its FY2025 earnings guidance.
Elevance to Report Q2 Earnings: Will Rising Costs Pressure Profits?
ELV's second-quarter earnings may face pressure as rising costs and lower Medicaid memberships offset strong revenue gains.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT - Summit Therapeutics ( NASDAQ:SMMT )
NEW YORK, July 14, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ( "Summit" or the "Company" ) SMMT. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Intuit ( NASDAQ:INTU ) , AstraZeneca ( NASDAQ:AZN )
The Benzinga Stock Whisper Index highlights five stocks each week seeing more interest from readers than normal. Several stocks on the list could be impacted by the new "Big Beautiful Bill." Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?
MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.
2 Top Stocks Down 16% and 17% This Year to Buy and Hold
Most people love a bargain. investors do too. Purchasing shares of companies that can perform well over long periods is already pretty exciting, but it's even more so when they can be scooped up from the discount bin.
Why Is AbbVie Stock Trading Higher On Thursday? - AstraZeneca ( NASDAQ:AZN ) , AbbVie ( NYSE:ABBV )
IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. ABBV, on Thursday, announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT protein platform, for oncology and ...
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug - Merck & Co ( NYSE:MRK ) , Verona Pharma ( NASDAQ:VRNA )
Merck will pay $107 per ADS in a $10-billion acquisition of Verona Pharma. FDA approved Verona's Ohtuvayre in June 2024 as a novel COPD maintenance therapy. Get daily-updated rankings across momentum, growth, value, trends, and quality to spot the strongest stocks in any market. Merck & Co. Inc.
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.
2 Soaring Stocks With More Upside Potential to Buy and Hold
Is it worth it to buy a stock after it experiences significant market gains? The answer is, it depends. Some companies don't have much growth fuel left in the tank after a nice run, while others still boast significant upside potential after juicy gains.
Why AstraZeneca Stock Got Thumped on Thursday
AstraZeneca ( NASDAQ: AZN ) might soon be on the hook for an eventual 11-figure payout, and investors weren't all that comfortable with this. A Bloomberg article published Thursday morning said that the company is pursuing what might end up being an expensive partnership with a biotech.A cautious ...
Why Summit Therapeutics Stock Soared 8% Higher Today
One day before the July Fourth holiday, the stock of clinical-stage biotech Summit Therapeutics ( NASDAQ: SMMT ) exploded like a powerful fireworks display. Shares of the cancer-focused company leaped by 8%, on a media report that a well-known peer was interested in a licensing deal.
AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment - AstraZeneca ( NASDAQ:AZN ) , Summit Therapeutics ( NASDAQ:SMMT )
AstraZeneca may pay up to $15 billion for rights to Summit's lung cancer drug, ivonescimab. Bob Duggan owns nearly 75% of Summit, which is valued at $17.4 billion. From tariffs to inflation, macro risks are rising-Matt Maley reveals how he's trading it all, live this Wednesday July 9 at 6 PM ET.
Wall Street Analysts Believe Summit Therapeutics ( SMMT ) Could Rally 63.02%: Here's is How to Trade
The mean of analysts' price targets for Summit Therapeutics (SMMT) points to a 63% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS ( ON ) Inhibitors with Ivonescimab in RAS Mutant Tumors - Summit Therapeutics ( NASDAQ:SMMT ) , Revolution Medicines ( NASDAQ:RVMD )
REDWOOD CITY, Calif. and MIAMI, June 30, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. RVMD, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics, Inc.
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS ( ON ) Inhibitors with Ivonescimab in RAS Mutant Tumors
REDWOOD CITY, Calif. and MIAMI, June 30, 2025 ( GLOBE NEWSWIRE ) -- Revolution Medicines, Inc. ( Nasdaq: RVMD ) , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics, Inc. ( Nasdaq: SMMT ) , a biopharmaceutical ...
2 Stocks Too Cheap to Ignore at These Prices
The S&P 500 flirted with bear-market territory earlier this year. Although it has mostly recovered, plenty of companies are still dealing with issues that have led to poor performances. Some of them have excellent prospects, though, making their current situations a great opportunity for ...
Merck Moves Past 50-Day Average: How to Play MRK Stock Now
MRK breaks above its 50-day average but near-term headwinds and weak China sales challenge the bullish case.
2 Dividend Stocks to Buy and Never Sell
There are excellent reasons to invest in dividend stocks, including the fact that they typically outperform their non-dividend-paying peers in delivering strong market returns over long periods.However, just because a company pays a dividend doesn't make it attractive in and of itself.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT - Summit Therapeutics ( NASDAQ:SMMT )
NEW YORK, June 15, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ( "Summit" or the "Company" ) SMMT. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Why Summit Therapeutics Stock Tanked Today
An analyst's downbeat new take on Summit Therapeutics ( NASDAQ: SMMT ) pushed its stock downward on Hump Day. At the end of Wednesday, the shares had booked a loss of over 11% in price as investors absorbed the negative take.
This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Core Natural Resources ( NYSE:CNR ) , Coinbase Global ( NASDAQ:COIN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Canaccord Genuity analyst Carey MacRury initiated coverage on Gold Royalty Corp.
Will Merck's Keytruda Continue to Drive Growth Amid Looming LOE?
MRK leans on Keytruda for growth as exclusivity loss nears, with new combos and launches aiming to ease reliance.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT - Summit Therapeutics ( NASDAQ:SMMT )
NEW YORK, June 10, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ( "Summit" or the "Company" ) SMMT. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Pfizer Stock Down Almost 11% YTD: Should You Buy the Dip?
PFE lags the market as COVID sales drop and patent losses loom, but new drugs and cost cuts may fuel a comeback.
Summit Therapeutics Inc. Company Investigated by the Portnoy Law Firm - Summit Therapeutics ( NASDAQ:SMMT )
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 06, 2025 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises Summit Therapeutics Inc. ( "Summit" or "the Company" ) SMMT investors that the firm has initiated an investigation into possible ...
2 Soaring Stocks Wth More Upside Potential
Although fundamental investing wisdom tells us to "buy low," it may still be worthwhile to purchase shares of top companies following significant runs. Any point can be considered low -- even after massive gains -- provided there is plenty of upside left.
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.
Down 36.7% in 4 Weeks, Here's Why Summit Therapeutics ( SMMT ) Looks Ripe for a Turnaround
Summit Therapeutics (SMMT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
OXB Highlights the Launch of its Innovation and Technology Excellence Board
Oxford, UK - 03 June 2025: OXB ( LSE: OXB ) ( "the Company" ) , a global quality and innovation-led cell and gene therapy CDMO, today highlights the launch of its Innovation and Technology Excellence Board ( ITEB ) .
Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results
SMMT plunges 31% as its NSCLC drug shows strong PFS but misses statistical significance on survival data.
3 No-Brainer Healthcare Stocks to Buy in June
A new month has arrived. Investors now have a fresh opportunity to buy great stocks. Three Motley Fool contributors believe they've found no-brainer healthcare stocks to buy in June. Here's why they like Amgen ( NASDAQ: AMGN ) , Vertex Pharmaceuticals ( NASDAQ: VRTX ) , and Summit Therapeutics ( ...
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?
Shares of Summit Therapeutics ( NASDAQ: SMMT ) tanked more than 30% on Friday, May 30. Such dramatic price swings aren't unusual in the biotechnology industry. in this case, disappointing data from an important clinical trial drove the stock down.Stock markets have a tendency to sell first and ...
Chinese biotech firm Akeso sinks after US partner's cancer-drug setback
Chinese biotech firm Akeso, whose cancer drug has been hailed as a breakthrough for the nation's pharmaceutical industry, suffered a setback after less favourable clinical data dashed hopes for a quick US regulatory approval. Akeso's shares fell 11.6 per cent to HK$73.65 in the morning session on ...
Temu Parent PDD, Regeneron Pharmaceutical And Burlington Stores Are Among Top 11 Large-Cap Losers Last Week ( May 26-May 30 ) : Are The Others In Your Portfolio? - PDD Holdings ( NASDAQ:PDD ) , Burlington Stores ( NYSE:BURL ) , Regeneron Pharmaceuticals ( NASDAQ:REGN )
Summit Therapeutics stock declined after announcing topline results from its Phase 3 HARMONi trial. Regeneron Pharmaceutical shares fell after mixed results from its AERIFY-1 and AERIFY-2 studies for smoker's lung disease.
Dow Edges Higher; Dell Shares Fall After Q1 Results - BioLine Rx ( NASDAQ:BLRX ) , CollPlant Biotechnologies ( NASDAQ:CLGN )
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index edging higher on Friday. The Dow traded up 0.05% to 42,238.88 while the NASDAQ fell 0.74% to 19,033.46. The S&P 500 also fell, dropping, 0.24% to 5,898.22. Consumer staples shares jumped by 1% on Friday.
Why Summit Therapeutics Plunged Today
Shares of Summit Therapeutics ( NASDAQ: SMMT ) have plunged 31% as of 1:23 p.m. ET Friday, following the release of some trial data this morning.Summit has been a tremendous winner over the past year, as its bispecific antibody lung cancer drug ivonescimab outperformed prior standards of care in ...
Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint - Summit Therapeutics ( NASDAQ:SMMT )
Ivonescimab plus chemo cut disease progression risk by 48% vs. chemo alone ( HR=0.52 ) . Fatal TEAEs were lower with ivonescimab ( 1.8% ) vs. chemo alone ( 2.8% ) in Phase 3 trial. Unlock your all-in-one trading dashboard with real-time alerts, rankings, and stock ideas-60% off ends ...
Pfizer's Mega Deal Highlights China's Rising Role In Global Pharma
The pharma giant Pfizer has bought international rights to the experimental cancer therapy and will take a $100 million equity stake in the Chinese drug developer The mega deal for rights to the Chinese biotech's cancer drug drove 3SBio's stock price to a seven-year high
Is Pfizer Stock a Buy After This $1.25 Billion Investment?
Pfizer ( NYSE: PFE ) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.However, the pandemic receded, and revenue in this area dropped off a cliff.
